500 episodes listed below
Oncology evidence translated into clinical decisions.
Research To Practice | Oncology Videos is a clinically focused oncology education series built around interviews, faculty lectures, case reviews, and meeting proceedings. Its strongest moments translate data, biomarkers, toxicity management, and treatment sequencing into the decisions clinicians face in practice.
PRESS PLAY
Research To Practice | Oncology Videos is built for clinicians who want oncology evidence explained in the language of practice. The series favors interviews, journal-club reviews, case discussions, faculty lectures, and symposium-style proceedings over casual conversation. It is dense by design. Recent episodes move across endometrial cancer, prostate cancer, non-small cell lung cancer, metastatic bladder cancer, and several breast cancer settings, but the underlying question stays consistent: what should a clinician do differently now? The show often starts with a treatment landscape, then narrows toward biomarkers, data, toxicities, and sequencing decisions. Endometrial cancer coverage tracks how molecular subsets have complicated an older low-grade versus high-grade framework. It asks where PARP inhibitors may fit, especially around mismatch repair status, BRCA mutations, homologous recombination questions, cost, and added toxicity. Nursing-focused antibody-drug conjugate education brings the same evidence lens into implementation. Eye exams, prophylactic drops, dose modification, and patient instruction become core clinical details rather than afterthoughts. Prostate cancer conversations examine terminology, androgen pathway sensitivity and resistance, adherence assumptions, oral therapy, injectable schedules, and the limits of claims-based real-world data. Lung cancer journal-club segments concentrate on ctDNA after surgery and what a positive result may signal for recurrence and survival risk. Breast cancer episodes spend careful time on tissue versus liquid biopsy, discordant biomarker detection, ESR1, PIK3CA, PI3 kinase pathway biology, receptor status, and future precision oncology trials. The bladder cancer case-review format grounds treatment strategy in a metastatic presentation and response to enfortumab vedotin plus pembrolizumab. The tone is professional and cautious. It does not chase simple takeaways when the evidence is still unsettled. Instead, it keeps circling back to what is known, what is uncertain, and what matters for the person receiving treatment. The strongest episodes make complex mechanisms usable without flattening them. This is not introductory cancer education. It is a working reference for oncology professionals who need to keep current while preserving clinical judgment.
Made for: Designed for oncologists, oncology nurses, advanced practice clinicians, pharmacists, fellows, and medically fluent listeners following cancer treatment advances. It is best suited to people comfortable with endpoints, biomarkers, drug classes, and toxicity management.
What sets it apart: The series combines evidence with practical bedside reasoning, moving from molecular mechanism to patient selection, adverse-event planning, and treatment sequencing. It stands apart by keeping uncertainty visible instead of reducing every study to a single conclusion.
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.
Based on 5 episodes we listened to · September 2026
Clinical interviews connect emerging cancer therapies to evidence limits, treatment tradeoffs, toxicity management and the practical work of oncology care.
Neil Love builds each program around a tightly defined treatment question, then gives a clinical investigator room to work through the evidence and the decisions it changes.
A baseline eye exam becomes gripping when your idea of suspense is dose modification.
Press play if you want
Short reviews from the PlayNext desk, based on the episodes we processed.
A clinical map of endometrial cancer that follows the data into the messy parts.
This review frames endometrial cancer as a field in motion, moving from a simple low-grade, high-grade split toward molecular subsets, mutation-driven options, and a more layered treatment map.
Practical ADC nursing guidance centered on eye exams, eye drops, and dose decisions.
The session offers oncology nurses a practical look at antibody-drug conjugates, with Dr. Kathleen Moore moderating Courtney Arnn, Jamie Carroll, Dr. Eddie Guerin, and Dr. Heather MacArthur.
A clear, careful review of prostate cancer labels, adherence evidence, and emerging treatment research.
This episode frames prostate cancer terminology as a practical sorting problem, using Dr. Neal Love's discussion with Dr. McKay to clarify APMS, APMR, HSPC, and CRPC.
A clinically grounded look at how CD19-directed therapy may shift from salvage care toward lower-burden treatment.
This single-episode review gives acute lymphoblastic leukemia a practical, forward-looking treatment frame, with Dr. Neil Love questioning Dr. Bijal Shah of Moffitt Cancer Center on CD19-directed strategies.
A focused review of CELMoDs, pivotal trials, and the role extramedullary disease may play in multiple myeloma.
Dr Neil Love's conversation with medical oncologist Dr Paul Richardson of Dana-Farber Cancer Institute frames CELMoDs as a developing piece of the multiple myeloma story.
Critical care evidence, carefully talked through.
Clinical research, reduced to its practical signal.
Evidence translated into clinical next steps.
Dr.
Dr.
Dr.
Dr.
A panel of experts discuss current patterns of care for first-line and maintenance therapy in extensive-stage small cell lung cancer, including survey results from community oncologists.
Research To Practice | Oncology Videos examines oral SERDs and PI3K/AKT/mTOR-pathway agents in hormone receptor-positive breast cancer during a session held with the 2026 ASCO Annual Meeting.
At the 51st Annual ONS Congress, David O'Malley, Brad Monk, Katie Schleneker, and Jacqueline Shaver discuss ovarian-cancer genetics, PARP inhibitors, bevacizumab, and folate-receptor-alpha testing for oncology nurses.
The host opens with a practical question about the treatment landscape in endometrial cancer.
Dr.
Medical oncologist Dr.
Dr.
Dr.
Dr.
A rapid case review of metastatic urothelial bladder cancer featuring expert discussion of a patient treated with enfortumab vedotin plus pembrolizumab.
This episode discusses first-line and maintenance therapy for ER-positive, HER2-positive metastatic breast cancer, featuring expert insights and survey data.
Dr.
Dr.